Agilon Health Under Investigation for Securities Fraud Violations

Agilon Health is being investigated for securities fraud violations after the company's CEO and board director stepped down and withdrew its full-year 2025 earnings guidance. Shares of Agilon fell 27% in after-hours trading. The DJS Law Group is investigating claims on behalf of investors for potential violations of securities laws.

Agilon Health, Inc. (NYSE: AGL) is under scrutiny following the sudden resignation of its CEO and board director, Steven Sell, and the withdrawal of its full-year 2025 earnings guidance. The company's stock price plummeted by over 27% in after-hours trading on August 4, 2025 [1].

The Schall Law Firm, Pomerantz LLP, and Bragar Eagel & Squire, P.C. have all announced investigations into potential securities fraud violations by Agilon and its officers [1][2][3]. These law firms are encouraging investors who suffered losses to contact them to discuss their legal rights.

The investigations focus on whether Agilon issued false or misleading statements and failed to disclose material information to investors. The company announced the resignation of Steven Sell and withdrew its full-year 2025 financial guidance in the same press release, which may have contributed to the significant drop in its stock price [1][2].

Agilon's second-quarter 2025 financial results also missed expectations, reporting a net loss of $0.25 per share and revenue of $1.4 billion, down 6% year-over-year [4]. The company cited ongoing leadership transition, shifts in market dynamics, and the rollout of new performance visibility tools for suspending its full-year 2025 guidance [4].

Investors who purchased or acquired Agilon shares and suffered a loss are encouraged to contact the law firms conducting the investigations to discuss their legal rights. The Schall Law Firm can be reached at 310-301-3335 or via email at bschall@schallfirm.com [1]. Pomerantz LLP can be contacted at 646-581-9980, ext. 7980 or via email at newaction@pomlaw.com [2]. Bragar Eagel & Squire, P.C. can be reached at (212) 355-4648 or via email at investigations@bespc.com [3].

References:
[1] https://www.businesswire.com/news/home/20250804620055/en/AGL-Investors-Have-Opportunity-to-Join-agilon-health-inc.-Fraud-Investigation-with-the-Schall-Law-Firm
[2] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-agilon-health-inc-agl-ce7c5ed2d18cf62c
[3] https://www.morningstar.com/news/globe-newswire/9510146/agilon-alert-bragar-eagel-squire-pc-is-investigating-agilon-health-inc-on-behalf-of-agilon-stockholders-and-encourages-investors-to-contact-the-firm
[4] https://ih.advfn.com/market-news/article/14072/agilon-health-shares-plunge-after-q2-miss-leadership-shakeup-and-suspended-guidance